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Abstract
Dystrophic neurites and activated microglia are one of the main neuropathological charac-
teristics of Alzheimer’s disease (AD). Although the use of supplements with omega-3 fatty
acids has been associated with reduced risk and lessened AD pathology, it still remains elu-
sive whether such a treatment could affect dystrophic neurites (DNs) formation and micro-
glia/macrophage behavior in the early phase of disease. We analyzed the effects of short-
term (3 weeks) fish oil supplementation on DNs formation, tau hyperphosphorylation, Amy-
loid-beta peptide 1–42 (Aβ42) levels and microglial/macrophage response to AD pathology
in the parietal cortex of 4-month-old 5xFAD mice, a mouse model of AD. The present study
shows for the first time that short-term FO supplementation applied in presymptomatic
stage of AD, alters the behaviour of microglia/macrophages prompting them to establish a
physical barrier around amyloid plaques. This barrier significantly suppresses DNs forma-
tion through the reduction of both Aβ content and tau hyperphosphorylation. Moreover, the
short-term FO treatment neither suppresses inflammation nor enhances phagocytic proper-
ties of microglia/macrophages in the response to Aβ pathology, the effects most commonly
attributed to the fish oil supplementation. Our findings suggest that fish oil consumption may
play an important role in modulating microglial/macrophage response and ameliorating the
AD pathology in presymptomatic stage of Alzheimer’s disease.
Introduction
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease and the main form
of progressive dementia in elderly [1]. It is characterized by cognitive deficits that initially
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affect learning and memory, leading to the overall cognitive decline as the disease progresses.
Although the AD clinical symptoms such as memory loss and impaired cognition occur in the
older age it is estimated that the pathological processes underlying AD begin to develop even a
few decades earlier [2]. Therefore, developing treatments for the presymptomatic phase of the
disease is gaining in importance.
Defining feature of AD pathology is the formation of amyloid plaques, structures composed
of fibrillar amyloid-β organized in a β-sheet conformation. Amyloid-β protein (Aβ) is the piv-
otal mediator of neuronal cell loss in the AD brain [3–5] with Aβ42 found to be the most toxic
form [6, 7]. Plaques are mostly encircled by a halo of diffuse Aβ42, surrounded by dystrophic
neurites (DNs) and activated glia [5, 8]. The areas of diffuse Aβ42 were recently named “hot-
spots” and they are considered as the zones of greater neuro-toxicity [9]. Dystrophic neurites
surrounding the plaques represent the initial phase of neurodegeneration. These varicose and
beaded neurites are characterized by extensive microtubule disruption, due to the abnormal
hyperphosphorylation of tau protein, and inhibited anterograde and retrograde trafficking
[10, 11].
Prolonged microglial activation has an important role in the pathogenesis of AD [12, 13].
The distinctive feature of microglial behavior in the AD brain is their noticeable clustering
around fibrillar Aβ deposits, which are also in close proximity to dystrophic neurites [14, 15].
However, the exact role of microglia in AD progression is still controversial.
The post-mortem studies as well as functional imaging studies have revealed that the
changes in the parietal lobe, besides those in the temporal and frontal cortex, contribute to the
AD progression [16–18]. Furthermore, these changes are gaining focus as a potential marker
for the early diagnosis of AD in accordance with the ‘last-developed–first-atrophied’ concept
[19]. The higher cognitive association areas, which mature after the primary areas, show the
first signs of functional decline and grey matter atrophy [19, 20]. The involvement of the parie-
tal cortex during the early phase of AD is likely due to its strong connectivity with other brain
areas, a role in memory retrieval [21] and the wide range of cognitive functions relying on its
proper functioning [22].
It has been shown that specific components of our diet can affect the progression of AD
[23, 24] and docosahexaenoic acid (DHA) is one of them. The levels of DHA are decreased in
brains and serums of AD patients [25, 26], and ω-3 polyunsaturated fatty acids (ω-3 PUFA)
supplementation had become of a major interest as potential adjunctive treatment for AD
patients. In humans, positive effects of DHA or eicosapentaenoic acid (EPA) supplementation
have been seen only in cognitively healthy participants and participants with mild cognitive
impairment [27]. Numerous clinical trials on patients with established AD revealed that EPA
and DHA supplementation did not slow the rate of cognitive decline compared to the placebo
[28]. In mouse AD models oral intake of PUFAs and fish oil (FO), a rich source of essential
PUFAs—DHA and EPA has been associated with the decreased amyloid deposition in the
early stages of AD and a reduced risk of AD if applied before the onset of AD pathology [29–
32]. However, the effect of FO supplementation on neuritic pathology in the early phase of the
disease has not been addressed so far.
Considering that the appearance of the DNs represents an early event that precedes neuro-
nal loss, we aimed to examine whether the modification in dietary consumption via the addi-
tion of FO, in the presymptomatic phase of AD pathology, could attenuate or even prevent the
progression of the DNs formation. To this purpose we have chosen the 5xFAD mouse model
[33], which displays a rapid deposition of Aβ and a massive loss of pyramidal neurons [34]
with the initial structural insults of neuronal cells appearing between 4 to 6 months of age [35].
We analyzed the effects of the short-term (3 weeks) FO treatment on DNs formation, p-Tau
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(Ser416) and Aβ42 levels, and on the distribution, number and localization of microglia/mac-
rophages in 4-month-old 5xFAD mice.
Materials and methods
Animals and procedures
Ethics statement. All animal procedures were in compliance with Directive (2010/63/EU)
on the protection of animals used for experimental and other scientific purposes and were
approved by the Ethical Committee for the Use of Laboratory Animals (resolution No 01-06/
13) of the Institute for Biological Research “Sinisa Stankovic”, University of Belgrade. Minimal
numbers of animals were used and all efforts were made to minimize animal suffering.
Experimental animals and fish oil treatment. Three months old 5xFAD mice (B6SJL-Tg
(APPSwFlLon, PSEN1�M146L �L286V) 6799Vas) from The Jackson Laboratory, stock num-
ber: 34840-JAX/5XFAD [33] were used for all experiments. Mice were divided into two experi-
mental groups: control group (marked as 5xFAD) and treated group (marked as 5xFAD FO).
The fish oil used in current study was ‘Omega 3’, commercial fish oil for human consumption
standardized to 12% DHA and 18% EPA (Dietpharm-Atlantic Group, Croatia). Treated ani-
mals received 100 μl of commercial fish oil per day by oral gavage as previously described [30].
The control group received the same volume of the water, also by oral gavage. The animals
were housed under standard conditions (23 ± 2˚C, 60–70% relative humidity, 12 h light/dark
cycles, with the lights switched on at 07:00; free access to food and water; n = 3 per cage). The
discomfort following oral gavage, capture, handling and restraint were minimized, due to the
refinements in housing, husbandry and care and good practice for substance administration.
Sample preparation. Following 3 weeks of FO treatment, when reached age of 3 months
and 3 weeks, animals were anesthetized with ketamine (Ketamidor, Richter pharm, Germany)
in dosages of 250mg/kg. Mice were perfused with ice-cold phosphate-buffered saline (PBS),
brains were harvested, and the cortex was extracted, quickly frozen, and stored at −80˚C until
use for RNA and protein analysis.
RNA and protein analysis
Quantitative real-time PCR. Quantitative real-time PCR was performed using the ABI
Prism 7700 Sequence Detection System (PE Applied Biosystems) to analyze the induction of
inflammatory cytokine mRNAs, following the manufacturer’s instructions. Briefly, total RNA
was extracted from the cortical tissue using TRIzol reagent. For cDNA synthesis, 1μg of total
RNA was transcribed with TaqMan reverse transcription reagents using random hexamers.
The cDNA was stored at −20˚C until further use. Relative quantification of TNFα and IL-1β
mRNAs was performed by real-time RT-PCR with the Applied Biosystems TaqManGene
Expression Assays (TNFα - Cat No. 4331182, IL-1β –Cat.No. 4351372; Thermo Fisher Scien-
tific). GAPDH was included as an endogenous control to correct for differences in interassay
amplification efficiency (ID Rn99999916_s1; Applied Biosystems). Each sample was run in
triplicate and the mean values of each Ct were used for further calculations. Quantification
was performed by the 2 −ΔΔCt method. The results obtained by RT-PCR were analyzed in RQ
Study add-on software for the 7700 v 1.1 SDS instrument, with a confidence level of 95%
(P< 0.05).
Enzyme-linked immunosorbent assay. Enzyme-linked immunosorbent assay (ELISA)
was used to quantify the cortical level of TNF-α. TNF-α ELISA kit (ab100747, Abcam) was
used according to the manufacturer’s recommendations. Tissue was homogenized on ice in
the extraction buffer recommended by the manufacturer (100 mM Tris, pH 7.4, 150 mM
NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate) with 1 mg/
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mL of protease inhibitor cocktail (cOmplete, Sigma-Aldrich) and 0.01 mg/mL of phosphatase
inhibitor cocktail (P5726, Sigma-Aldrich). The protein concentrations were determined using
a Micro BCA protein assay kit (Pierce, Rockford, IL). The absorbance at 450 nm was measured
with an iMark Microplate Absorbance Reader (Bio-Rad).
Western blot analysis. The extracted cortical tissue was homogenized in 10 vol (w/v) of
RIPA buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% SDS, 10 mM EDTA pH
8.0, 10 mM EGTA pH 7.2, 0.5% Triton X-100), followed by centrifugation (21 000 rcf, 30 min,
4ºC); the supernatant was collected. Protein concentrations were determined using the Micro
BCA Protein Assay Kit (Pierce Biotechnology). Equal amounts of proteins (30 μg per lane)
were loaded and separated by 10% SDS acrylamide gel electrophoresis and blotted onto nitro-
cellulose membranes (Amersham Bioscience). The membranes were blocked at room temper-
ature for 1 h in 5% nonfat dry milk in Tris-buffered saline/0.1% Tween 20 (TBST). The
membranes were incubated with rabbit monoclonal anti-phospho-Tau (Ser416) (1:500;
D7U25, Cell Signaling Technologies, USA) in TBST, overnight at +4C˚. The membranes were
than incubated with the HRP labeled secondary anti-rabbit antibody (1:2000; sc-2370, Santa
Cruz, USA) in TBST for 1 h at room temperature. Three subsequent washes with 0.1% TBST
were performed between each step. The signal was detected by enhanced chemiluminescence
(ECL, Amersham Bioscience) and exposure of an X-ray film. All films were analyzed by densi-
tometry using the computerized image analysis program ImageQuant ver. 5.2 (Amersham).
The Ponceau S staining of the membranes served as endogenous control. The relative values of
the signals (normalized to the corresponding Ponceau S staining) were determined and further
statistically analyzed.
Histological analysis
Preparation of tissues for histological analysis. Following the perfusion with ice-cold
phosphate-buffered saline (PBS), brains were harvested, and one hemi-brain drop fixed in 4%
paraformaldehyde/PBS and cryopreserved in graded sucrose solutions (10–30% w/v sucrose/
PBS) for sectioning. The brains were frozen in isopentane, cooled on dry ice and stored at
-80˚C. Every third coronal section (20 μm thick) was collected and stored at -20˚C.
Amyloid plaque staining. For amyloid plaque staining, Thioflavin S (ThioS) and Amylo-
Glo (BioSense, TR-300-AG) staining was used. ThioS was used for double staining with amy-
loid beta 42 antibody. Following protocol for amyloid beta 42 immunostaining, sections were
washed three times in 0.01 PBS, and incubated in 0.01% ThioS solution in 50% ethanol for 8
min at RT. Stained sections were washed briefly in 80% and 96% ethanol, rinsed in distilled
water and mounted onto glass slides using fluorescent mounting medium (Dako). AmyloGlo
staining was used for triple labeling with ionized calcium binding adaptor molecule 1 (Iba-1)
and amyloid 4g8 antibodies. Before incubation with antibodies sections were transferred into a
70% solution of ethanol for 5 minutes at RT. The slides were then rinsed in distilled water for 2
minutes. Sections were transferred for 10 min to a 1:100 of AmyloGlo dissolved in 0.9% saline
solution, rinsed in 0.9% saline solution for 5 minutes, and briefly rinsed in distilled water. Fol-
lowing AmyloGlo staining, sections were incubated with Iba-1 and amyloid 4g8 antibodies.
Immunohistochemical analysis
Immunofluorescence. Sections were blocked in 1% bovine serum albumin (BSA) in PBS
for 1h in RT, incubated overnight at 4˚C with primary antibodies listed in Table 1, followed by
appropriate secondary antibodies (anti-mouse or anti-rabbit conjugated to Alexa 488 or 568;
Invitrogen) used at the 1:250 concentration in PBS for 2h at room temperature (RT). Sections
incubated in parallel without primary antibody were included as negative controls for
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autofluorescence and background binding of the secondary antibody. Sections were mounted
with Fluorescent Mounting Medium (Dako).
Quantitative analysis of Aβ42 clusters and SMI31-labeled DNs. Images were captured
on an Axio Observer Microscope Z1 using an AxioVision 4.6 software system (Carl Zeiss, Ger-
many) at a magnification of 5×, 10× and 40×. For quantification of Aβ42 clusters and SMI31--
labeled dystrophic neurites we used available software provided by the National Institute of
Health (NIH, USA)—Image J, Version 1.74. The software analyzed each cross-section. We
have designated a threshold of the fluorescence intensity. When setting the limit value for anal-
ysis we have opted for the automatic value (Maximum Entropy), instead of manual adjust-
ment, in order to perform further analysis equally in all cross-sections and to reduce faults.
Based on given parameters we produced values of the surface of Aβ42 clusters. The values
were further processed statistically and expressed as percentage of parietal cortex covered by
Aβ42 and average surface of Aβ42 clusters.
Analyses of SMI31-positive spheroids number and % of area covered with SMI31 immu-
nostaining were done using Image J with threshold processing (Max Entropy) and low surface
area limit set to 50μm2. The low surface area limit was set in order to exclude SMI31-positive
particles of lower surface which correspond to SMI31 immunostaining of normal (non-dystro-
phic) neurites. Based on given parameters we produced values of the surface of SMI31-positive
spheroids number and % of area. The values were further processed statistically.
Confocal microscopy and image analysis of colocalization between Iba-1 and Aβ 4G8.
Amyloid β and Iba-1 labelling were visualized with a Leica TSC SP8 confocal microscope
(Leica Microsystems) equipped with 405/488/552 nm lasers using 40x/1.30 oil immersion lens.
Images were taken with a step size of 1μm. Emission of fluorescently labelled Aβ and Iba-1
were collected sequentially. All images were taken with a 1024×1024 pixel resolution and 8-bit
colour depth. Colocalization analysis was performed in ImageJ software (NIH, USA) using
JACoP plugin [36] and the degree of colocalization between Iba-1 and Aβ4G8 was measured
using the Pearson correlation coefficient (PCC). PCC measures the strength of a linear rela-
tionship between fluorescent intensities from the two images and produces values ranging
from 1 (perfect positive correlation) to -1 (perfect inverse correlation), with 0 representing a
random distribution [37].
Confocal microscopy and quantification of Iba1-positive microglia/macrophages. For
Iba-1 imaging conditions were the same as described above. The number of Iba-1-positive
microglia/macrophages were counted in layers III to VI in parietal part of the somatosensory
cortex in 1 field per section under the area of the screen (400μm x 550μm) in 3 sections per
animal (n = 8 animals per each group). The sections were analyzed by a researcher unaware of
the treatment.
Confocal microscopy and quantification of plaque perimeter covered by microglia/mac-
rophages. For Iba-1 and Amylo Glo imaging conditions were the same as described above.
Confocal images of plaques selected for their similar size, location and cortical layer (layers III
to VI in parietal part of the somatosensory cortex) were obtained for quantitative imaging
using a a Leica TSC SP8 confocal microscope. Images were numbered randomly and blinded
Table 1. Primary antibodies used in this study.
antibody against catalogue No. host/clonality manufacturer Dilution
Amyloid β 42 700254 rabbit monoclonal Invitrogen 1:500
Purified Abeta 4G8 800701 mouse monoclonal BioLegend 1:2000
SMI31 LN#E10214GF mouse monoclonal Covance 1:5000
Iba-1 019–19741 rabbit polyclonal WAKO 1:250
https://doi.org/10.1371/journal.pone.0216726.t001
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for analysis. All images were analyzed in ImageJ software. Five optical slices through the center
of the plaque were used for analysis. On each slice, the intersection between the tips of micro-
glia/macrophages process and the plaque perimeter were identified manually. The proportion
of the plaque perimeter covered by microglia/macrophages processes was calculated by sum-
ming the arcs of plaque perimeter that colocalized with microglial/macrophage processes. For
each measurement, the average of results for 5 optical slices was reported as a measurement
for the individual plaque.
Statistical analysis. Significant differences between the data sets were determined using
STATISTICA software, Ver. 6.0, StatSoft. Further statistical analysis was made using relative
values. Considering that data did not meet the criteria of a normal distribution, nonparametric
Man-Whitney U test was used for comparisons among two experimental groups. Statistical
significance was set at P< 0.05.
Results
Three weeks of fish oil supplementation ameliorates neuritic dystrophy
and tau hyperphosphorylation in parietal cortex of 5xFAD mice
Swollen, dystrophic neurites surrounding amyloid plaques represent one of the hallmarks of
AD pathology. Since neuritic dystrophy inevitably leads to neuronal cell death, it is of vital
interest to prevent this aspect of AD pathology. In order to determine whether fish oil supple-
mentation can affect the neuritic dystrophy we stained sections from the parietal cortex of the
control and FO-treated 5xFAD mice with SMI31 antibody. In non-supplemented 5xFAD mice
in the vicinity of amyloid plaques, SMI31 staining revealed swollen, dystrophic neurites (Fig
1A and 1D asterisks). However, the analysis of brain sections of FO-supplemented 5xFAD ani-
mals showed that most of the neurites have normal (non-dystrophic) appearance (Fig 1B and
1E), and are similar to neurites observed in the cortex of age-matched wild-type controls (Fig
1C and 1F).
In order to size the effect of the FO treatment, we measured the SMI31-positive spheroids
number and % of SMI31 immunopositive area in the parietal cortex of untreated and FO-
treated 5xFAD animals (Fig 1J). The analysis revealed that FO treatment significantly lowered
the number of SMI31-positive spheroids (by 48.6%, MWU test, p = 0.03) and the percentage
of the area covered by SMI31 (by 50.62%, MWU test, p = 0.018) when compared to untreated
5xFAD animals (Fig 1K). Thus, the short-term (3 weeks) fish oil supplementation is able to
suppress neuritic dystrophy in the parietal cortex of 5xFAD mice.
Dystrofic neurites are characterized by abnormally hyperphosphorylated tau protein that
becomes incompetent in maintaining the stability of microtubules. Western blot analysis of p-
Tau (Ser416) was performed in order to determine whether fish oil supplementation sup-
presses neuritic dystrophy by affecting the level of tau hyperphosphorylation. The analysis
revealed that the level of p-Tau (Ser416) was significantly decreased (by 36%) in FO-treated as
compared to untreated 5xFAD animals (MWU, p = 0.033) (Fig 1L and 1M).
Fish oil supplementation reduces the area covered by Aβ42 and the average
size of Aβ42 clusters in the parietal cortex
It is widely accepted that amyloid β (Aβ42) that surrounds amyloid plaques represents the
main cause of neuritic dystrophy in Alzheimer’s pathology. Since we showed that fish oil sup-
plementation is able to suppress neuritic dystrophy in the parietal cortex of 5xFAD mice (Fig
1), we wanted to assess whether it is able to alter the total amount of Aβ42 in this cortical
region. The immunostaining of parietal cortex of control and FO-treated 5xFAD mice with
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anti-Aβ42 antibody (Fig 2) revealed that in both control and FO-treated 5xFAD mice, Aβ42
localization was observed mainly surrounding the plaques of insoluble amyloid β (stained with
Fig 1. FO supplementation ameliorates neuritic dystrophy through suppression of abnormal tau
hyperphosphorilation in the parietal cortex of 5xFAD mice. (A and D) Axonal dystrophies (arrows) surrounding
amyloid plaques (P) in 4-month-old 5xFAD mice; (B and E) Brains of FO-supplemented 5xFAD mice showing
significant suppression of dystrophic axons around plaques; (C and F) wild type mice showing absence of dystrophic
neurites (G-I) Print screen of ImageJ SMI31 analysis (Max Entropy threshold). (J) Percentage of SMI31-positive
spheroids larger than 50μm2 in untreated and FO-treated 5xFAD mice. (K) Percentage of SMI31 coverage of parietal
cortex in untreated and FO-treated 5xFAD mice (low surface area limit set to 50μm2). (L) Representative immunoblot
of p-Tau (Ser416) in untreated and FO-treated 5xFAD mice. (M) Changes in p-Tau (Ser416) protein in the cortex of
5xFAD and 5xFAD FO mice were revealed by Western blot analysis. The data represent mean ± S.E.M. value;
�p< 0.05. Scale bar (D-F) - 5μm.
https://doi.org/10.1371/journal.pone.0216726.g001
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Thioflavin-S) (Fig 2C–2H). In order to size the effect of the FO treatment, we measured the
surface area of the parietal cortex stained with anti-Aβ42 (Fig 2A and 2B). The analysis of sur-
face percentage immunostained with Aβ42 revealed that FO treatment significantly lowered
(by 49.14%) the area covered by Aβ42 when compared to the untreated 5xFAD animals
(MWU test, p = 0.0047) (Fig 2I). Moreover, Image J analysis revealed that FO supplementation
significantly reduced the average size of Aβ42 clusters (by 29.6%) in the parietal cortex of
treated 5xFAD animals when compared to the untreated 5xFAD animals (MWU test,
p = 0.0209) (Fig 2J).
The Aβ42 “hot-spots” are the sites of greater neurotoxicity and we wanted to see if the
decrease in Aβ42 covered surface around plaques relates to the lower occurrence of DNs. Dou-
ble staining with Aβ42 and SMI31 antibodies revealed that the areas with higher incidence of
DNs display the greater Aβ42 halo around the plaques (AmyloGlo+) (Fig 3A–3D). The oppo-
site was observed in FO treated 5xFAD animals: the decreased surface of the Aβ42 halo over-
laps with the decreased incidence of swollen, dystrophic neurites (Fig 3E–3H).
Fish oil supplementation does not affect the levels of proinflammatory
cytokines and phagocytosis of Aβ42 by microglia/macrophages in the
parietal cortex of 5xFAD mice
Since the phagocytosis of Aβ protein by microglia/macrophages has been proposed as an Aβ-
lowering mechanism in AD [38, 39], we wanted to see whether the observed increase in Iba-1
+ cell number correlates with the increased colocalization of Aβ42 in microglia surrounding
Fig 2. FO supplementation significantly reduces Aβ42 in the parietal cortex of 5xFAD mice. (A) The Aβ42 coverage
of the parietal cortex in untreated and in (B) FO treated 5xFAD mice. (C-E) Representative images of Aβ42 clusters in
parietal cortex of untreated and treated (F-H) 5xFAD mice. (I) Quantification of Aβ42 coverage of parietal cortex of
untreated vs. treated 5xFAD mice from 8 animals for each group. Data represents mean ± s.e.m. (J) Quantification of
average Aβ42 cluster surface in the parietal cortex of untreated vs. treated 5xFAD mice. Scale bar 10μm.
https://doi.org/10.1371/journal.pone.0216726.g002
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the plaques. This information was assessed by measuring colocalization of Iba-1 and Aβ42
from the images obtained by confocal microscopy. The degree of colocalization between Iba-1
and Aβ42 was calculated using the Pearson correlation coefficient. The obtained PCC values
for non-supplemented and FO-supplemented animals (r = 0.125063 and r = 0.14805, respec-
tively) varied between 0.3 and -0.3 which is indicative of very weak to no correlation (Fig 4C
and 4D) suggesting that although the FO treatment increased the number of microglia/macro-
phages around plaques, it did not affect their phagocytic properties.
Given the well described anti-inflammatory action of fish oil [40, 41], we next examined the
expression of TNFα an IL-1β, the main proinflammatory cytokines expressed by activated
microglia. The RealTime PCR analysis revealed no difference in IL-1β mRNA expression levels
among Wt, 5xFAD and 5xFAD FO animals (Fig 4E). Although a tendency to alter the levels of
TNFα mRNA expression was observed following FO treatment, these changes did not reach
an overall statistical significance due to variation of TNFα mRNA expression levels between
the samples. Moreover, no changes were observed in the TNFα protein level among 5xFAD
and 5xFAD FO group (Fig 4F).
Fish oil supplementation significantly elevates the total number of
microglia/macrophages in the parietal cortex and the average number of
these cells associated with amyloid plaques, accompanied by the increased
plaque envelopment
Since ω-3 PUFAs may be protective against AD by modulating the immune response to Aβ
[42] we wanted to see whether the FO treatment had an effect on the number and distribution
of Iba-1 positive microglia/macrophages in 5xFAD mice. The quantification of microglia/
Fig 3. Decreased Aβ42 halo overlaps with the decreased incidence of DNs in FO treated mice. (A-D) Double staining of untreated 5xFAD mice
brain sections with the 4g8 and SMI31 antibodies revealed that the areas with higher incidence of DNs display the greater total Aβ halo around the
plaques (AmyloGlo+). (E-H) In the FO-treated 5xFAD animals the decreased surface of the Aβ halo overlaps with the decreased incidence of swollen,
dystrophic neurites.
https://doi.org/10.1371/journal.pone.0216726.g003
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macrophages number revealed that the FO treatment significantly increased (40.5%) the num-
ber of Iba-1+ cells in the parietal cortex of 5xFAD mice compared to the untreated mice (Fig
5A–5C) (MWU test, p = 0.00172). Namely, an average of 84 microglia/macrophages per field
was detected in fish oil-supplemented animals, while the significantly lower number of 50
microglia/macrophages per field was detected in non-supplemented animals.
Considering that fish oil supplementation led to the increase in an overall number of micro-
glia/macrophages in the parietal cortex, we next examined whether it affected the number of
plaque-associated microglia/macrophages. To that end we counted a number of Iba-1+ cells
with their processes pointed towards and permeated with the plaque surface of single plaques
(Fig 5D and 5E). An average of 2.93 plaque-associated Iba-1+ cells per single plaque was
counted in non-treated 5xFAD animals, while significantly higher number of 4.01 plaque-
Fig 4. FO supplementation does not affect the phagocytic properties of microglia/macrophages and levels of
proinflammatory cytokines. ((A,B) Representative confocal images showing absence of phagocytosis of Aβ42 by
microglia/macrophages as assessed by measuring colocalization of Iba-1 and Aβ42 immunostaining. (C)The obtained
PCC values for non-supplemented and (D) FO-supplemented animals from n>90 plaques from 8 animals for each
group. (E) The RealTime PCR analysis of TNFα an IL-1β. (F) TNFa protein levels as revealed by ELISA Scale bar (A,B)
- 10μm.
https://doi.org/10.1371/journal.pone.0216726.g004
Fish oil and presymptomatic Alzheimer’s disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0216726 May 16, 2019 10 / 18
Fig 5. FO supplementation affects the total number of microglia/macrophages, average number of plaque
associated microglia/macrophages and plaque envelopment. (A) Representative confocal images of Iba-1
immunolabeled microglia/macrophage in parietal cortex in untreated and (B) FO treated 5xFAD mouse. (C)
Quantification of number of Iba-1 positive microglia/macrophages in parietal cortex of untreated vs. treated 5xFAD
mice in from 8 animals for each group. Data represents mean ± s.e.m.(D) Representative confocal images of Iba-1
immunolabeled microglia/macrophages around AmyloGlo-labeled amyloid plaques in untreated and (E) FOtreated
5xFAD mice, larger magnification. (F) Quantification of number of plaque-associated microglia/macrophage in
untreated vs. treated 5xFAD mice in n>90 plaques from 8 animals for each group. Data represents mean ± s.e.m. (G)
Representative confocal images of Iba-1 immunolabeled microglial/macrophage processes (green) contacting
AmyloGlo-labeled amyloid plaques in untreated and (H) FO-treated 5xFAD mice. (I) Microglia/macrophage coverage
was quantified as the percentage of plaque perimeter contacted by microglial/macrophage processes in n>90 plaques
from 8 animals for each group. Data represents mean ± s.e.m. (J,K) Representative confocal images of the degree of
microglia coverage (Iba-1, green) versus extent of neuritic dystrophy (SMI31, red) around the plaque. (L,M)
Representative confocal images of Iba-1 immunolabeled microglia/macrophages (green) and Aβ42 (red) mutual
exclusion. Scale bar (A, B) - 50μm. Scale bar (D,E,G,H)– 10 μm. Scale bar (J,K,L-M)– 5μm.
https://doi.org/10.1371/journal.pone.0216726.g005
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associated Iba-1+ cells (MWU test, p = 0.000140) was counted in the parietal cortex of fish oil-
supplemented 5xFAD animals (Fig 5F). We next sought to understand whether the elevated
number of microglia/macrophages aggregating around plaques also affected the degree of pla-
que surface coverage by processes of these immune cells (Fig 5G and 5H). Our results revealed
that plaque surface coverage by microglial/macrophage processes was significantly elevated in
the FO-supplemented 5xFAD animals (MWU test, p<0.00001) and amounted to 62.55% of
total plaque surface, as compared to 49.32% of coverage in non-supplemented animals (Fig 5I).
Moreover, given that microglial/macrophage processes represent neuroprotective barrier
[9] the increased number of plaque-associated microglia/macrophages observed in FO-supple-
mented mice might be the consequence of neuroprotective properties of fish oil. Namely, our
data showed that plaque regions covered by microglia/macrophage had fewer dystrophic neur-
ites than those without microglial/macrophage processes (Fig 5J and 5K). Since microglial/
macrophage process distribution around the plaques is mutually exclusive with the localization
of Aβ42 (Fig 5L and 5M), the increased microglial/macrophage envelopment of amyloid pla-
ques in FO-supplemented mice might be responsible for the observed reduction of Aβ42 in
the parietal cortex of this animals. Thus, these data strongly suggest that increased envelop-
ment of amyloid plaques by microglial/macrophage processes represent a critical determinant
of the neuroprotection driven by FO supplementation.
Discussion
Neurodegeneration in AD is a process that evolves during prolonged period of time and when
the first clinical symptoms occur the disease is so far advanced that it leaves little or no options
of reverting damage that has been already inflicted. The onset of neuritic dystrophy appears in
the early phase of pathology, the latent phase, thus presenting the window of opportunity for
the potential treatments that can suppress the development of these pathological changes and
disrupt the progression of the disease. The 5xFAD mouse represents a valuable model for
studying the effects of different treatments on various aspects of AD related pathology as this
AD mouse model develops the profound loss of cortical neurons by 12 months, with the initial
structural insults appearing between 4 to 6 months of age [34, 35].
In the present study 5xFAD mice were treated for three weeks with FO in the latent phase
of disease when the changes in animal behavior are not yet apparent. We demonstrated that
even a short treatment with FO reduced the Aβ42 accumulation and DNs formation around
the plaques, concurrently increasing the average microglial number and microglial plaque
envelopment in the parietal cortex of 5xFAD mice.
So far, the progression of neuritic dystrophy has been linked to the Aβ protein accumula-
tion around amyloid plaques in the AD brain [3, 43, 44]. It has been shown that Aβ mediates
microtubule disruption via abnormal hyperphosphorylation of tau [45], and microtubule-
based transport impairment that leads to the development of neuritic dystrophy and increased
APP cleavage and Aβ production within these dystrophic neurites [5]. The microtubule-asso-
ciated protein tau plays a major role in maintaining the normal morphology of the neurons, as
it promotes microtubule assembly and stabilization. In the brain of AD patients, tau protein is
abnormally hyperphosphorylated and thus become incompetent in maintaining the stability of
the microtubules, directly affecting the morphology and biological functions of the neurons.
The recent data from the study in 5xFAD mice [46] supports the prevailing amyloid cascade
hypothesis [47], implying that hyperphosphorylation of tau is downstream of amyloid pathol-
ogy, triggering the neurodegeneration and severe neuronal loss. Indeed, the anti-Aβ antibody
treatment induces the reduction in the number and size of dystrophic neurites as soon as 3
days after Aβ deposits were cleared by this treatment [48]. The present study revealed that the
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short-term FO supplementation significantly suppressed DNs formation through the reduc-
tion of both Aβ content and tau hyperphosphorylation. This is in accordance with previous
research showing that DHA increases neuronal survival by directing amyloidogenic processing
of APP towards nonamyloidogenic processing, effectively reducing Aβ release [31]. In addi-
tion, DHA treatment has also been shown to improve microtubule stability and maintenance
of active compensatory microtubule-associated proteins [49].
Besides the reduction of Aβ content, the anti-inflammatory action of fish oil is also well
described [40, 41, 50–52], and many of its pleiotropic effects have been ascribed to this prop-
erty. Numerous data indicate that DHA anti-inflammatory effects are accompanied by an
increase in the phagocytic activity of microglial cells [53, 54]. Recent studies of fish-derived
omega-3 supplementation in patients with mild cognitive impairment have shown polariza-
tion of macrophages to an intermediate M1-M2 phenotype that is optimal for Aβ phagocytosis
and the stabilization of cognitive decline [54, 55]. However, our study showed for the first time
that short-term FO supplementation neither suppresses inflammation nor enhances phago-
cytic properties of immune cells in the response to Aβ pathology, but it changes the behaviour
of these cells prompting them to establish a physical barrier around amyloid plaques.
The classical M1 activation of macrophages is characterized by elevated pro-inflammatory
cytokines and impaired phagocytic capacity [56, 57], while the M2 state is characterized by
secretion of anti-inflammatory cytokines and elevated phagocytic capacity [58–60]. However,
the M1/M2 activation states represent the polar extremes of myeloid cell activation. There is a
large diversity and graduation of phenotypic states in peripheral monocyte-derived macro-
phages, in particular under conditions of chronic inflammation [61, 62]. It is increasingly rec-
ognized that responses of microglia to CNS injuries are more complex than M1 and M2
macrophage activation, and are likely modulated by the type of injury, timing and environ-
ment; possibly involving a continuum of states [63, 64].
It has been shown that activated microglia migrate to amyloid deposits early in the patho-
genesis of a mouse model of AD [65]. However, in vivo studies monitoring plaque-microglia
interaction did not observe any plaques being cleared by this microglial response [65]. This
suggests that, unless further activated [66], microglia do not successfully clear plaques but
instead may well restrict their growth, leading to the observed steady state of plaque size after
initial formation [9, 65].
It is, therefore, possible that short-term fish oil treatment brings microglia/macrophages in
a state of increased migration towards Aβ deposits enhancing the envelopment of amyloid pla-
ques by their processes, without affecting inflammatory or phagocytic properties of these cells.
The importance of these findings is strengthened with the recent discovery that plaque
micro-regions not covered by microglia represent hot-spots rich in the protofibrillar Aβ42 [5],
a form of Aβ that is significantly more neurotoxic than larger Aβ aggregates[67, 68]. The accu-
mulated microglial cells act as a barrier that reduces the uncovered plaque surface and conse-
quently the number of hotspots of active Aβ polymerization. The microglial barrier can
restrict further polymerization of the growing amyloid fibrils preventing their elongation and
promoting their bending, thus shielding the surrounding neurites [5]. The strong enhance-
ment of microglial/macrophage plaque envelopment observed in FO treated 5xFAD mice can
thus represent the mechanism underlying the observed reduction of Aβ42 hotspots around
plaques in the parietal cortex. The substantial neuritic dystrophy around fibrillar plaques with
greater protofibrilar Aβ42 halo further highlights the necessity for the reduction of, not the
number of plaques, but the amount of protofibrilar Aβ42 as the major cytotoxic component.
As a rule, the overall degree of neuritic dystrophy around plaques is inversely correlated to the
extent of microglia/macrophage plaque envelopment. However, the diffident reduction of
DNs after anti-Aβ immunotherapy [48], regardless of a robust increase in the microglia
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envelopment, implies that negative effects of the immunotherapy might counteract the benefi-
cial effects of the microglia barrier. The failure of such [69] and numerous other promising
therapeutic approaches can be partly explained with their implementation in the later phase of
the AD progression.
Condello and colleagues [9] emphasized that microglia envelopment was most effective
around smaller plaques suggesting that microglia barrier is most prominent at the initial stages
of fibrillar amyloid deposition and becomes less effective as the disease progresses. Similarly,
studies of microglia ablation in later stages of amyloidosis did not show any effect on plaque
number or neuritic dystrophy [70] indicating that it is increasingly difficult to treat symptoms
after the disease occurrence. Therefore, the enhancement of the microglial/macrophage envel-
opment of the plaques and the consequential reduction of Aβ42 hotspots induced by the FO
supplementation suggests a novel mechanism by which fish oil can inhibit the development of
neuritic dystrophy.
This study provides evidence that neuroprotective effect of FO in the early phase of AD pro-
gression occurs through the modulation of microglia/macrophage number and behavior and
underlines the necessity to elucidate the responsible molecular pathways. Several mechanisms
are known to underlie omega-3-mediated neuroprotection, such as suppression of cell death,
inhibition of inflammation, and promotion of neurogenesis [31]. In addition, omega-3 PUFA
modulates microglia cell number and morphology in response to intracerebroventricular amy-
loid-β 1–40 in mice [42]. Also, documented DHA effects on lipid rafts, cholesterol homeosta-
sis, amyloid burden and microtubule stability [12], can be responsible for the therapeutic
effects of the FO supplementation. Aβ pathology is initiated at least two decades before cortical
tau pathology and the onset of clinical AD symptoms[71,72], giving ample time for the preven-
tive treatments to either delay or to ameliorate this debilitating disease. This is why the devel-
opment of medications for early prevention and treatment, in accordance with the global
epidemiological status, are considered a vital research goal.
Conclusions
The present study shows for the first time that short-term FO supplementation in presymp-
tomatic stage of AD, changes the behaviour of microglia/macrophages prompting them to
establish a physical barrier around amyloid plaques. This barrier significantly suppresses DNs
formation through the reduction of both Aβ content and tau hyperphosphorylation. It is inter-
esting however, that short-term FO treatment neither suppresses inflammation nor enhances
phagocytic properties of microglia/macrophages in the response to Aβ pathology, the effects
most commonly attributed to the fish oil supplementation.
Revealing whether fish oil affects both microglia and macrophages in the same way, and
understanding the precise mechanisms involved in this newly identified effect of fish oil, repre-
sent the future directions in elucidating its neuroprotective capacity in AD and other neurode-
generative disorders. Fish oil as a potential treatment in AD patients has a narrow window of
applicability limited to the early stages of the disease. However, FO supplementation as a pro-
phylactic intervention targeted to the enhancement of microglia/macrophage barrier may rep-
resent a promising strategy that offers effective neuroprotection.
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